Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children
Clinical Infectious Diseases2009Vol. 48(4), pp. 389–396
Citations Over TimeTop 1% of 2009 papers
Iain Stephenson, Jane Democratis, Angie Lackenby, Teresa McNally, James Smith, Manish Pareek, Joanna Ellis, Alison Bermingham, Karl G. Nicholson, Maria Zambon
Abstract
Drug resistance emerges at a higher rate in influenza A subtype H1N1 virus than in influenza A subtype H3N2 or influenza B virus after tiered weight-based oseltamivir therapy. Virological surveillance for patterns of drug resistance is essential for determination of antiviral treatment strategies and for composition of pandemic preparedness stockpiles.
Related Papers
- → Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir(2001)148 cited
- → Neuraminidase inhibitor resistance in influenza viruses(2007)93 cited
- → A Novel Small-Molecule Inhibitor of the Avian Influenza H5N1 Virus Determined through Computational Screening against the Neuraminidase(2009)63 cited
- → Frequency of Drug-resistant Viruses and Virus Shedding in Pediatric Influenza Patients Treated With Neuraminidase Inhibitors(2011)50 cited
- → Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia(2003)12 cited